For the year ending 2025-12-31, SMTI made $103,117,982 in revenue. -$37,562,606 in net income. Net profit margin of -36.43%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Net revenue | 103,117,982 | 86,672,425 | ||
| Cost of goods sold | 7,520,969 | 8,139,901 | ||
| Gross profit | 95,597,013 | 78,532,524 | ||
| Selling, general and administrative | 78,716,999 | 76,559,863 | ||
| Research and development | 5,072,483 | 5,703,362 | ||
| Depreciation and amortization | 2,661,873 | 4,923,224 | ||
| Change in fair value of earnout liabilities | - | 1,938,451 | ||
| Asset impairment charges | 1,841,120 | - | ||
| Total operating expenses | 88,292,475 | 85,247,998 | ||
| Operating income | 7,304,538 | -6,715,474 | ||
| Interest expense | 6,759,800 | 3,128,395 | ||
| Share of losses from equity method investments | -952,466 | -90,007 | ||
| Interest income | 3,672 | 21,978 | ||
| Gain on disposal of property and equipment | 10,932 | - | ||
| Total other income (expense) | -7,697,662 | -3,196,424 | ||
| Net loss from continuing operations | -393,124 | - | ||
| Net loss from discontinued operations (including asset impairment charge of 26,472,407 in 2025) (note 3) | -37,174,923 | - | ||
| Net loss | -37,568,047 | -9,911,898 | ||
| Net loss attributable to noncontrolling interest from continuing operations | -5,441 | - | ||
| Less total net loss attributable to noncontrolling interest | -5,441 | -247,351 | ||
| Net loss attributable to sanara medtech shareholders | -37,562,606 | -9,664,547 | ||
| Basic EPS | -4.36 | -1.14 | ||
| Diluted EPS | -4.36 | -1.14 | ||
| Basic Average Shares | 8,623,028 | 8,484,224 | ||
| Diluted Average Shares | 8,623,028 | 8,484,224 | ||
Sanara MedTech Inc. (SMTI)
Sanara MedTech Inc. (SMTI)